Furthermore, administration of BAY 11–7,082, an NF-kB antagonist, corrected the altered vascular responsiveness to norephinephrine in the diabetic mesenteric vascular bed and hyperglycemia-induced apoptosis in VSMCs (Benter et al., 2015). Here, NFKB1 is linked to Hyperglycemia.